Characteristics of Patients Presenting with Neurologic Complaints
| Characteristic | Data |
|---|---|
| Age at start of treatment (y) | |
| Overall | Median, 70 (range, 58–90) |
| ≥65–84 | 92% (46) |
| ≥85 | 10% (5) |
| Gleason score at diagnosis | |
| 6 | 4% (2) |
| 7 | 38% (19) |
| 8 | 12% (6) |
| 9 | 36% (18) |
| 10 | 8% (4) |
| Unknown | 2% (1) |
| Mean follow-up time ± SD (mo) | 12.04 ± 2.87 |
| Time from diagnosis to first cycle of 177Lu-PSMA-617 (mo) | Median, 68.37 (range, 15.9–354.2) |
| ECOG | |
| 0 or 1 | 96% (48) |
| ≥2 | 4% (2) |
| History of hypertension | 30% (15) |
| History of diabetes mellitus | 10% (5) |
| Sites of metastases | |
| Bone | 82% (41) |
| Lymph node | 68% (34) |
| Liver | 2% (2) |
| Lung | 6% (3) |
| Number of bone metastases | |
| 1–4 | 2% (1) |
| 5–10 | 8% (4) |
| >10 | 72% (36) |
| Previous systemic therapies | |
| Androgen deprivation therapy | 100% (50) |
| Taxane chemotherapy (docetaxel, cabazitaxel) | 100% (50) |
| Androgen biosynthesis inhibitors (abiraterone) | 80% (40) |
| Androgen receptor inhibitors (enzalutamide, bicalutamide, apalutamide, darolutamide) | 100% (50) |
| Carboplatin | 38% (19) |
| Immunotherapy (sipuleucel-T) | 8% (4) |
| 223Ra | 8% (4) |
| Total cycles of 177Lu-PSMA-617 | |
| 2 | 4% (2) |
| 3 | 14% (7) |
| 4 | 22% (11) |
| 5 | 22% (11) |
| 6 | 38% (19) |
ECOG = Eastern Cooperative Oncology Group.
Data are percentage followed by number in parentheses (total n = 50), unless otherwise specified.